Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Study of Colon Pathology in HER2+ Breast Cancer Patients Treated With Neratinib
2019-001896-35Phase 2Completed
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Oct 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of neratinib in breast cancer, sponsored by Puma Biotechnology, Inc. Primary endpoint: Change in colon biopsy pathology after 28 days of neratinib. Started Oct 2019; status: completed.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-001896-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001896-35.